Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer's disease
Alzheimer's & Dementia · 2024-08 · 20 (8) · 5617-5628
DOI: 10.1002/alz.14073 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 28.06.2024. Verfasst von Viswanath Devanarayan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Eisai Inc., Clinical Evidence Generation, Nutley, New Jersey, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Amyloid beta-Peptides, Brain, Positron-Emission Tomography. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eisai Inc..
Themen: Demenz
Abstract (Originalsprache)
BACKGROUND This study investigated the potential of phosphorylated plasma Tau217 ratio (pTau217R) and plasma amyloid beta (Aβ) 42/Aβ40 in predicting brain amyloid levels measured by positron emission tomography (PET) Centiloid (CL) for Alzheimer's disease (AD) staging and screening. METHODS Quantification of plasma pTau217R and Aβ42/Aβ40 employed immunoprecipitation‐mass spectrometry. CL prediction models were developed on a cohort of 904 cognitively unimpaired, preclinical and early AD subjects and validated on two independent cohorts. RESULTS Models integrating pTau217R outperformed Aβ42/Aβ40 alone, predicting amyloid levels up to 89.1 CL. High area under the receiver operating characteristic curve (AUROC) values (89.3% to 94.7%) were observed across a broad CL range (15 to 90). Utilizing pTau217R‐based models for low amyloid levels reduced PET scans by 70.5% to 78.6%. DISCUSSION pTau217R effectively predicts brain amyloid levels, surpassing cerebrospinal fluid Aβ42/Aβ40's range. Combining it with plasma Aβ42/Aβ40 enhances sensitivity for low amyloid detection, reducing unnecessary PET scans and expanding clinical utility. CLINICALTRIALS.GOV IDENTIFIERS NCT02956486 (MissionAD1), NCT03036280 (MissionAD2), NCT04468659 (AHEAD3‐45), NCT03887455 (ClarityAD) Highlights Phosphorylated plasma Tau217 ratio (pTau217R) effectively predicts amyloid‐PET Centiloid (CL) across a broad spectrum. Integrating pTau217R with Aβ42/Aβ40 extends the CL prediction upper limit to 89.1 CL. Combined model predicts amyloid status with high accuracy, especially in cognitively unimpaired individuals. This model identifies subjects above or below various CL thresholds with high accuracy. pTau217R‐based models significantly reduce PET scans by up to 78.6% for screening out individuals with no/low amyloid.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Eisai Inc., Clinical Evidence Generation, Nutley, New Jersey, USA.
- Department of Mathematics, Statistics and Computer Science, University of Illinois Chicago, Chicago, Illinois, USA.
- Eisai Ltd., Clinical Evidence Generation, Hatfield, UK.
- Carle Illinois College of Medicine, Urbana, Illinois, USA.
- Department of Molecular and Integrative Physiology, University of Illinois Urbana-Champaign, Urbana, Illinois, USA.
- Beckman Institute for Advanced Science and Technology, Urbana, Illinois, USA.
ORCID-Profile: Viswanath Devanarayan
Förderung
- Eisai Inc.
Zitieren
APA
Devanarayan, V., Doherty, T., Charil, A., Sachdev, P., Ye, Y., Murali, L. K., Llano, D. A., Zhou, J., Reyderman, L., Hampel, H., Kramer, L. D., Dhadda, S., & Irizarry, M. C. (2024). Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer's disease. Alzheimer's & Dementia, 20(8), 5617-5628. https://doi.org/10.1002/alz.14073
Vancouver
Devanarayan V, Doherty T, Charil A, Sachdev P, Ye Y, Murali LK, et al. Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer's disease. Alzheimer's & Dementia. 2024;20(8):5617-5628. doi:10.1002/alz.14073
BibTeX
@article{Devanarayan2024,
author = {Devanarayan, Viswanath and Doherty, Thomas and Charil, Arnaud and Sachdev, Pallavi and Ye, Yuanqing and Murali, Leema Krishna and Llano, Daniel A and Zhou, Jin and Reyderman, Larisa and Hampel, Harald and Kramer, Lynn D and Dhadda, Shobha and Irizarry, Michael C},
title = {Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer's disease},
journal = {Alzheimer's & Dementia},
year = {2024},
volume = {20},
number = {8},
pages = {5617--5628},
doi = {10.1002/alz.14073}
}
EUVIMED